Our network meta‐analysis summarizes the latest information and provides a proposed ranking of PFS, OS, ORR, PFS with BM, SAEs, and AEs leading to treatment discontinuation for all of the marketed ALKis in ALK‐positive NSCLC. Here, ALK is linked to non-small cell lung carcinoma.